DBV Technologies' Participation at ACAAI Annual Meeting
DBV Technologies (NASDAQ: DBVT) is set to take part in a significant scientific event, the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. Scheduled for November 6-10, this prestigious meeting will occur in a vibrant location, drawing experts from various fields of allergy and immunology.
Product Theater Presentation
During the event, DBV Technologies will host an engaging Product Theater, titled "Harnessing Immune Plasticity to Alter the Path of Food Allergy". This session will feature an esteemed panel of allergists, including Drs. Gideon Lack, Hugh Sampson, George du Toit, Kirsten Perrett, and Matthew Greenhawt, who will delve into immunological and clinical evidence supporting the early intervention in food allergy treatment strategies. A highlight of this presentation will be Dr. Perrett sharing vital information about an upcoming Phase 2 clinical trial that aims to investigate the efficacy and safety of the VIASKIN Peanut patch in enabling peanut allergic infants, aged between 6 to 12 months, to safely consume dietary peanut after a substantial treatment period.
Important Session Details
- Date: Saturday, November 8, 2025
- Time: 11:35 a.m. to 1:00 p.m. ET
- Location: West Hall E
Focus on Early Intervention
Addressing the evolving landscape of food allergy management, Dr. Gideon Lack noted a shift towards a proactive approach, stressing the significance of early allergen introduction and immunomodulatory interventions. The upcoming study centered on the VIASKIN Peanut patch aims to clarify whether early interventions can facilitate safe dietary peanut inclusion in vulnerable infants.
Research Presentation at the Meeting
The ACAAI event will also feature Dr. Matthew Greenhawt presenting findings from the EPITOPE study's open-label extension, as part of the "Distinguished Industry and Late-breaking Oral Abstract" session. This presentation is scheduled for the evening of November 8, making it a key moment for attendees interested in the latest research outcomes related to food allergies.
DBV Technologies’ Commitment to Food Allergy Research
Reiterating their dedication to advancing food allergy management, Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies, emphasized the significance of the Product Theater as a platform for unveiling the first Phase 2 study aimed at enabling ad lib consumption of peanuts. This innovative approach follows promising results from the EPITOPE study, underscoring DBV's commitment to serving young patients in the food allergy domain. Additionally, the company is exploring a potential BLA filing for the VIASKIN Peanut patch targeting toddlers aged 1-3 years, under an Accelerated Approval Pathway as previously discussed with the FDA.
Key Oral Scientific Presentation Details
- Title: Long-Term Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: EPOPEX End-of-Study Results
- Session: Distinguished Industry & Late-breaking Oral Abstracts - Session 2
- Date: Saturday, November 8, 2025
- Session Time: 4:30 to 6:00 p.m. ET
- Presentation Time: 4:43 p.m. ET
- Location: Room W231
Booth and Event Sponsorship
At this year’s conference, DBV Technologies will showcase their advancements at booth #711, along with sponsoring the 34th Annual FIT Bowl™. This engaging game-show style competition will challenge teams from various allergy, asthma, and immunology training programs, enhancing knowledge and awareness in the field.
About DBV Technologies
DBV Technologies is devoted to developing innovative treatment options for food allergies and various immunologic conditions that lack adequate solutions. Their proprietary VIASKIN patch technology represents a groundbreaking approach to managing food allergies, offering hope to millions affected, including many children. By employing epicutaneous immunotherapy (EPIT), DBV aims to educate the immune system towards desensitization against allergens. The company actively conducts research trials for their VIASKIN Peanut technology focused on young children aged 1-7 years, fulfilling a significant need in pediatric allergy care.
Company Overview and Contact Information
DBV Technologies operates from Châtillon, France, while having a North American presence in Warren, NJ. Their shares are publicly traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and ADSs, representing five ordinary shares, are available on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).
For further inquiries, feel free to reach out to:
Investor Contact:
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact:
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Frequently Asked Questions
What is the focus of DBV Technologies' participation at ACAAI?
The focus includes discussing the innovative approaches for managing food allergies, especially involving their VIASKIN Peanut patch in infants.
Who will present at the Product Theater?
A notable panel of allergists including Drs. Gideon Lack, Hugh Sampson, and others will present the session.
What major study will be discussed at the meeting?
Dr. Perrett will present a planned Phase 2 clinical trial regarding the effectiveness of the VIASKIN Peanut patch.
When is the Company's oral scientific presentation scheduled?
The oral scientific presentation is on Saturday, November 8, 2025, at 4:43 p.m. ET.
How does DBV Technologies aim to impact food allergy management?
DBV Technologies is committed to transforming food allergy care through innovative treatments and clinical studies targeting young patients.
